ProMIS Neurosciences 2024 PMN310 Alzheimer's Targeting Misfolded Proteins

ProMIS Neurosciences presents PMN310, a potential Alzheimer's treatment targeting toxic amyloid-beta oligomers. Phase 1a data shows good tolerability with appropriate CSF levels supporting potential for monthly dosing and subcutaneous administration. The program aims to improve potency, safety, and compliance over existing therapies with no expected ARIA liability.